Search Results

Innate Pharma SA announced that in an abstract published on 14 May 2024 for the European Hematology Association 2024 Congress on SAR443579/IPH6101, submitted by Sanofi, it was mentioned that the molecule received breakthrough designation.

Big Pharma had plenty of drama to keep journalists busy this quarter, which painted an accurate portrait of the wild and wonderful world of biopharma.

Innate Pharma SA announced the voting results of its shareholders at the Annual General Meeting, which took place on May 23, 2024, in Marseille.

Innate Pharma SA announced that updated efficacy and safety results from the dose-escalation part of the Phase 1/2 study with SAR443579/IPH6101 from a joint research collaboration between Innate Pharma and Sanofi and ANKET® platform lead asset, were shared in an oral presentation at the European Hematology Association 2024 Congress in Madrid, Spain on Sunday, June 16 at 11:45 CEST.

Boston Pharma’s once-monthly injection efimosfermin alfa offers a convenient dosing option for MASH patients while also achieving promising rates of fibrosis and MASH improvement, according to a Phase II readout.

A handful of billion-dollar deals in the rare disease space highlights the uptick in Big Pharma’s investment, but it’s still extremely low compared to the money flowing to more common indications.

Regulatory News: Innate Pharma SA announced members of its executive team are scheduled to participate in the upcoming conferences, detailed below.

Innate Pharma SA announced favorable results from the Phase 2 TELLOMAK study with lacutamab in mycosis fungoides.

Innate Pharma SA reported its consolidated financial results for the quarter ending March 31, 2024.

Celon Pharma S.A. (CLN.WA) today announced the successful completion of a Phase 2 trial a JAK/ROCK dual inhibitor in the treatment of Rheumatoid Arthritis (RA).